-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 23, 2021, Triastek, the only 3D printing drug company in China, announced the establishment of product development and commercialization cooperation with Sperogenix Therapeutics, which focuses on the R&D and commercialization of rare disease drugs in China.
Jointly develop an improved new drug product T22 for patients with pulmonary hypertension (PAH).
According to the cooperative development agreement, Sandieji is responsible for the development and production of T22 preparations, and Shufang Pharmaceutical is responsible for clinical trials, registration and commercialization in the cooperation area.
Pulmonary hypertension is a serious and progressive chronic disease that can be affected by people of all ages regardless of gender or region.
In this cooperation, Triassic will use its proprietary MED®3D printing technology to develop a drug product T22 with programmed release characteristics and significantly simplify the dosing regimen in response to the medication needs of patients with pulmonary hypertension, aiming to reduce The patient's medication burden can improve the patient's long-term medication compliance.
Dr.
Mr.
About Triassic
Founded in July 2015, Sandieji is a global leader in the field of 3D printing drugs.
About Shufang Medicine
Shufang Medicine is a platform-based company focusing on the R&D and commercialization of rare disease drugs in China.
